Drug Information

Drug General Information
Drug ID
D0O3EP
Former ID
DNCL002921
Drug Name
SRT2379
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [522863]
Company
Sirtris
Target and Pathway
Target(s) NAD-dependent deacetylase sirtuin-1 Target Info Modulator [550534]
KEGG Pathway FoxO signaling pathway
AMPK signaling pathway
Glucagon signaling pathway
Amphetamine addiction
MicroRNAs in cancer
PANTHER Pathway p53 pathway
Pathway Interaction Database p73 transcription factor network
Signaling events mediated by HDAC Class III
E2F transcription factor network
HIF-2-alpha transcription factor network
Signaling events mediated by HDAC Class I
FoxO family signaling
Regulation of Androgen receptor activity
Regulation of retinoblastoma protein
Reactome RORA activates gene expression
Regulation of HSF1-mediated heat shock response
Circadian Clock
WikiPathways Integrated Pancreatic Cancer Pathway
SREBF and miR33 in cholesterol and lipid homeostasis
Integrated Breast Cancer Pathway
SREBP signalling
Androgen receptor signaling pathway
References
Ref 522863ClinicalTrials.gov (NCT01018628) A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers. U.S. National Institutes of Health.
Ref 550534SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.